The SEQUOIA study compared zanubrutinib to bendamustine plus rituximab in newly diagnosed chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients, including those with high-risk genetic features such as del(17p). After six years of follow-up, zanubrutinib helped patients live longer without disease progression and fewer patients had to switch to a new treatment. Zanubrutinib may help overcome poor prognosis typically associated with high-risk genetic features as the outcomes for patients with del(17p) were comparable to those without del(17p). The safety profile remained generally favorable and consistent over time.

The contents of the presentations above are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and/or efficacy for such investigational products or uses may be made.